Last reviewed · How we verify

NCT03781973

Bridging the Gap to Adult Diabetes Care

Completed NA Last updated 24 April 2025
What this trial tests

NA trial testing Data platform +Quality Performance feedback reports in Type1diabetes in 484 participants. Completed in 31 December 2022.

Timeline
1 June 2019
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorThe Hospital for Sick Children
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposehealth services research
Enrollment484
Start date1 June 2019
Primary completion31 December 2022
Estimated completion31 December 2022
Sites5 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

The Hospital for Sick Children

Who can join

Adults 16 to 19, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adolescents with type 1 diabetes face particular challenges related to having a chronic illness that requires daily intensive self-management and medical follow-up during a period when their social, developmental, educational, and family situations are in flux. When transitioning from pediatric to adult care, over a third of youth have a care gap of \>6 months. During this vulnerable period youth are at risk for acute life-threatening complications such as diabetic ketoacidosis, and for poor glycemic control, which confers an increased risk of chronic diabetes complications. Gaps in care may be a result of deficiencies in transition processes causing some young people to be poorly prepared for adult care and dissatisfied with the transition process. Ineffective transition can lead to decreased frequency of diabetes visits and an increased risk of adverse events in young adulthood. Further, risk factors such as psychiatric comorbidity and behavioural problems in adolescents with type 1 diabetes are associated with poor outcomes in early adulthood. Quality improvement initiatives can be designed to optimize care processes such as referral systems to adult diabetes providers. Our overall objective is to optimize care and outcomes for youth with diabetes as they transition to adult care. Specific Aim 1: To improve glycemic control in youth around the time of transition from pediatric to adult diabetes care Specific Aim 2: To evaluate the fidelity and quality of a quality improvement intervention designed to improve transition care processes and to identify contextual factors associated with variation in outcomes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. An assessment of adaptation and fidelity in the implementation of an audit and feedback-based intervention to improve transition to adult type 1 diabetes care in Ontario, Canada.
    Ahmad SZ, Ivers N, Zenlea I, Parsons JA, et al · · 2024 · cited 5× · PMID 38500183 · DOI 10.1186/s43058-024-00563-2
  2. Testing an audit and feedback-based intervention to improve glycemic control after transfer to adult diabetes care: protocol for a quasi-experimental pre-post design with a control group.
    Shulman R, Zenlea I, Shah BR, Clarson C, et al · · 2019 · cited 5× · PMID 31766999 · DOI 10.1186/s12913-019-4690-0
  3. An audit and feedback-based intervention to improve diabetes management in the year after transfer to adult type 1 diabetes care: A multi-center quasi-experimental study.
    Shulman R, Zenlea I, Ivers N, Austin PC, et al · · 2025 · cited 1× · PMID 39473047 · DOI 10.1111/dme.15444

Verify or expand the search:

Other recruiting trials for Type1diabetes

Currently open trials in the same condition.

Other The Hospital for Sick Children trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03781973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing